| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
8,649 |
6,200 |
$341K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
4,960 |
4,829 |
$120K |
| 88312 |
|
1,316 |
1,174 |
$63K |
| 88307 |
|
422 |
382 |
$59K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,769 |
1,641 |
$48K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,775 |
1,646 |
$48K |
| 80053 |
Comprehensive metabolic panel |
6,352 |
5,514 |
$35K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,463 |
3,237 |
$32K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,042 |
5,929 |
$30K |
| 88313 |
|
857 |
760 |
$29K |
| 36415 |
Collection of venous blood by venipuncture |
11,751 |
9,287 |
$24K |
| 88141 |
|
1,118 |
1,082 |
$22K |
| 80061 |
Lipid panel |
2,529 |
2,407 |
$19K |
| 88341 |
|
170 |
142 |
$19K |
| 88342 |
|
334 |
284 |
$16K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
457 |
440 |
$14K |
| 88304 |
|
613 |
550 |
$14K |
| 87077 |
|
2,249 |
2,065 |
$13K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,513 |
2,375 |
$12K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
198 |
187 |
$10K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
658 |
619 |
$8K |
| 87186 |
|
1,381 |
1,272 |
$8K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,265 |
1,144 |
$6K |
| 86780 |
|
535 |
523 |
$6K |
| 86850 |
|
578 |
567 |
$4K |
| 87070 |
|
667 |
625 |
$4K |
| 86762 |
|
300 |
299 |
$4K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
99 |
91 |
$4K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,014 |
768 |
$4K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
159 |
155 |
$3K |
| 84439 |
|
365 |
342 |
$2K |
| 88300 |
|
194 |
160 |
$2K |
| 87625 |
|
90 |
86 |
$2K |
| 85652 |
|
951 |
854 |
$2K |
| 82728 |
|
203 |
187 |
$2K |
| 87081 |
|
301 |
284 |
$2K |
| 87205 |
|
536 |
493 |
$2K |
| 81001 |
|
1,269 |
1,076 |
$2K |
| 86900 |
|
590 |
581 |
$1K |
| 86901 |
|
589 |
580 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
31 |
31 |
$1K |
| 85007 |
|
421 |
405 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
133 |
123 |
$1K |
| 85610 |
|
1,441 |
754 |
$1K |
| 86140 |
|
262 |
220 |
$925.68 |
| 86803 |
|
92 |
87 |
$872.43 |
| 84481 |
|
55 |
49 |
$687.76 |
| 85027 |
|
175 |
162 |
$683.89 |
| 80076 |
|
98 |
89 |
$581.51 |
| 83880 |
|
99 |
79 |
$489.89 |
| 87340 |
|
52 |
51 |
$372.27 |
| 83540 |
|
103 |
89 |
$350.66 |
| 83550 |
|
63 |
57 |
$325.29 |
| 88142 |
|
16 |
15 |
$270.12 |
| 82607 |
|
34 |
33 |
$250.25 |
| 87430 |
|
16 |
15 |
$231.06 |
| 82570 |
|
52 |
50 |
$175.62 |
| 82565 |
|
36 |
36 |
$141.07 |
| 81003 |
|
76 |
72 |
$133.81 |
| 87210 |
|
13 |
13 |
$116.16 |
| 80164 |
|
15 |
13 |
$78.62 |
| 86592 |
|
18 |
18 |
$77.14 |
| 82043 |
|
12 |
12 |
$37.13 |
| 83735 |
|
12 |
12 |
$32.68 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
1,937 |
1,159 |
$0.00 |
| 99001 |
|
246 |
234 |
$0.00 |
| G0476 |
Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test |
56 |
48 |
$0.00 |